These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 32445524)
1. Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients. Authors' reply. Kim GA; Lim YS Aliment Pharmacol Ther; 2020 Jun; 51(12):1440-1441. PubMed ID: 32445524 [No Abstract] [Full Text] [Related]
2. Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients. Dusheiko G Aliment Pharmacol Ther; 2020 Jun; 51(12):1439-1440. PubMed ID: 32445523 [No Abstract] [Full Text] [Related]
3. Letter: risk of developing hepatocellular carcinoma in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Authors' reply. Choi GH; Lim YS Aliment Pharmacol Ther; 2019 Sep; 50(5):619-620. PubMed ID: 31414529 [No Abstract] [Full Text] [Related]
4. Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma. Safaie P; Poongkunran M; Kuang PP; Javaid A; Jacobs C; Pohlmann R; Nasser I; Lau DT World J Gastroenterol; 2016 Mar; 22(12):3404-11. PubMed ID: 27022222 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis B e antigen and the risk of hepatocellular carcinoma. Yang HI; Lu SN; Liaw YF; You SL; Sun CA; Wang LY; Hsiao CK; Chen PJ; Chen DS; Chen CJ; N Engl J Med; 2002 Jul; 347(3):168-74. PubMed ID: 12124405 [TBL] [Abstract][Full Text] [Related]
6. Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Authors' reply. Kim GA; Lim YS Aliment Pharmacol Ther; 2020 Aug; 52(3):576-577. PubMed ID: 32656844 [No Abstract] [Full Text] [Related]
7. Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma. Chen YC; Liaw YF Aliment Pharmacol Ther; 2016 Jul; 44(2):210-1. PubMed ID: 27296691 [No Abstract] [Full Text] [Related]
8. Letter: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance. Jiang JF; Sun J; Shi J; Liu X Aliment Pharmacol Ther; 2017 May; 45(9):1286-1288. PubMed ID: 28370051 [No Abstract] [Full Text] [Related]
9. Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B-authors' reply. Kim GA; Lim YS Aliment Pharmacol Ther; 2021 Mar; 53(6):763. PubMed ID: 33599320 [No Abstract] [Full Text] [Related]
13. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Chen CH; Hung CH; Lee CM; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS Gastroenterology; 2007 Nov; 133(5):1466-74. PubMed ID: 17915220 [TBL] [Abstract][Full Text] [Related]
14. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients. Chen TM; Chang CC; Huang PT; Wen CF; Lin CC Aliment Pharmacol Ther; 2013 Jan; 37(2):243-51. PubMed ID: 23171385 [TBL] [Abstract][Full Text] [Related]
15. Letter: risk of developing hepatocellular carcinoma in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Huang R; Wang J; Yan X; Xia J; Wu C Aliment Pharmacol Ther; 2019 Sep; 50(5):618-619. PubMed ID: 31414546 [No Abstract] [Full Text] [Related]
16. Letter: Association of persistently high HBsAg levels during HBeAg-seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients-Authors' reply. Lin HC; Jeng WJ; Yang HI Aliment Pharmacol Ther; 2024 Jun; 59(11):1459-1461. PubMed ID: 38664887 [No Abstract] [Full Text] [Related]
17. Clinical, virologic and phylogenetic features of hepatitis B infection in Iranian patients. Bahramali G; Sadeghizadeh M; Amini-Bavil-Olyaee S; Alavian SM; Behzad-Behbahani A; Adeli A; Aghasadeghi MR; Amini S; Mahboudi F World J Gastroenterol; 2008 Sep; 14(35):5448-53. PubMed ID: 18803358 [TBL] [Abstract][Full Text] [Related]
18. Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection". Choi J J Hepatol; 2022 Nov; 77(5):1472-1474. PubMed ID: 35987276 [No Abstract] [Full Text] [Related]
19. Prevalence of naturally occurring surface antigen variants of hepatitis B virus in Korean patients infected chronically. Song BC; Kim SH; Kim H; Ying YH; Kim HJ; Kim YJ; Yoon JH; Lee HS; Cha CY; Kook YH; Kim BJ J Med Virol; 2005 Jun; 76(2):194-202. PubMed ID: 15834881 [TBL] [Abstract][Full Text] [Related]
20. Editorial: serum HBV RNA biphasic decline in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues-authors' reply. Liu S; Li W; Sun J Aliment Pharmacol Ther; 2020 Sep; 52(5):883-884. PubMed ID: 32852824 [No Abstract] [Full Text] [Related] [Next] [New Search]